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Evaluation of the Patient with Congestive Heart Failure 
and Ventricular Arrhythmias 
BERTRAM PITT, MD 
Although vasodltators and new inotropic agents 
have been shown to improve ventrkular functkn 
and reduce symptoms, their effect on mortaltty is 
uncertain. In view of our failure to reduce mortaltty 
in patients with coqestive heart faiture (CHF), the 
identlfkation and amelloratll of potentlllly revers- 
ible factors that might alter survival are crucial be- 
fore initiating therapy. The first step is to establish 
the diagnosis of CHF and the presence or absence 
of dilated congestive cardiomyopathy. The extent of 
myocardtal dy&nctkn, both rlght and left, must 
also be evaluated. In post-myocardial infarction pa- 
tients, left ventricular ejection fraction is an impor- 
tant indicator of prognosis during the ftrst 1 to 2 
years. However, in patients wtth chronk CHF and 
dilated cardiomyopathy, right ventricular ejection 
fraction may be a more effective predktor of surviv- 
T 
:h e goals of treatment in a patient with congestive 
heart failure (CHF) are two-fold: to improve symptoms 
and to increase survival (Table I). Although vasodila- 
tors and new inotropic agents improve ventricular 
function, reduce symptoms and enhance the quality of 
life, their effects on mortality are not yet c1ear.Q Simi- 
larly, while antiarrhythmic agents obviously decrease 
the incidence of arrhythmias in patients with CHF, 
they apparently do not lead to a subsequent reduction 
in sudden cardiac death. In 1971, the Framingham 
study found that the probability of dying within 5 years 
from the onset of CHF was 62% for men and 42% for 
women3 The investigators stated, “despite earlier rec- 
ognition and increasingly sophisticated and potent 
treatment of congestive heart failure, its clinical course 
and prognosis remains surprisingly grim and not much 
better than those for cancer in general.” Unfortunate- 
ly, this statement remains true 15 years later. 
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al. The presence, frequency and complextty of ven- 
tricular arrhythmias must be determined, because 
these arrhythmias may Independently increase the 
rtsk of sudden cardiac death In patlents wlth isch- 
emit cardiomyopathy. Their role in patlents with Id- 
iopathic cardiomyopathy is less certain. In addition, 
myocardial ischemla, left ventrkular dysklnesis or 
aneurysm, occult myocardltts and neurothrombosts 
formation must be ruled out. Detectton and correc- 
tion of serum electrolyte and neurohumeral abnor- 
malities are essential. Cur failure to reduce mortality 
in patients wtth CHF may not entirely lie in the lack 
of effective therapeutic agents but rather in our fail- 
ure to apply property the diagnostic and therapeutic 
approaches now available. 
(Am J Cardiol 1986;57:19B-24B) 
In view of our failure to reduce mortality in CHF 
patients with vasodilators, inotropic or antiarrhythmic 
agents, the identification and amelioration of poten- 
tially reversible factors that might alter survival are 
crucial before initiating therapy. This review focuses 
on the evaluation of patients with dilated congestive 
cardiomyopathy with particular emphasis on the pa- 
tient whose clinical course is complicated by ventricu- 
lar arrhythmias. The key points in the assessment of a 
patient with suspected dilated congestive cardiomyop- 
athy are outlined in Table II. 
Establishing the Diagnosis of Congestive Heart 
Failure and the Presence of Dilated Congestive 
Cardiomyopathy 
The diagnosis of CHF can usually be made by histo- 
ry and physical examination. On the other hand, the 
diagnosis of dilated congestive cardiomyopathy and its 
differentiation from other forms of heart failure, such 
as restrictive or constrictive cardiomyopathy, often re- 
quire laboratory investigation. It is important to ascer- 
tain whether a patient’s symptoms of fatigue, shortness 
of breath, dyspnea on exertion and pulmonary rales, if 
present, are primarily due to a cardiac, pulmonary or 
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TABLE I Goals in Treating a Patient with Congestive Heart 
Failure 
To improve symptoms: 
To enhance well-being and quality of life 
To increase exercise tolerance 
To improve survival: 
To prevent progressive cardiac failure 
To prevent sudden cardiac death 
To prevent thromboembolic episodes 
other cause. The standard chest x-ray may be of limit- 
ed value in this regard. The electrocardiogram, while 
occasionally helpful, is often misleading. Evidence of 
myocardial infarction may be absent in patients with 
ischemic cardiomyopathy and, conversely, Q waves or 
poor R-wave progression in the anterior chest leads 
may frequently be present in patients with idiopathic 
dilated cardiomyopathy. 4 The echocardiogram is, 
however, especially useful in establishing the diagnos- 
is of dilated cardiomyopathy, and in determining the 
presence of underlying congenital or valvular heart 
disease, pericardial effusion, hypertrophic cardiomy- 
opathy or heart failure due to diastolic dysfunction5 
Reversible causes of heart failure-such as anemia, 
volume overload, uremia, hemochromatosis, sarcoid 
heart disease, hypophosphatemia, hypoparathyroid- 
ism, pheochromocytoma, acromegaly, arteriovenous 
malformations and hyper- or hypothyroidism-should 
be ruled out.6-g The history may be especially valuable 
in detecting doxorubicin cardiomyopathy or radiation- 
induced restrictive cardiomyopathy. The ingestion of 
alcohol or other toxins in a patient with cardiomyopa- 
thy may also result in ventricular tachycardia (the 
“holiday heart syndrome”).1° 
Evaluating the Extent of Myocardial Dysfunction 
Determination of left ventricular (LV) ejection frac- 
tion (EF) is an important indicator of survival in the 
post-myocardial infarction patient. Schulze et aP1J2 
noted a relation between LVEFs of <40% and the 
occurrence of complex ventricular arrhythmias in post- 
infarction patients, and pointed out the importance of 
this relation in predicting the risk of sudden cardiac 
death. Results from the Multicenter Postinfarction Re- 
search Group have confirmed the value of the LVEF as 
a prognostic indicator in the first 1 to 2 years after 
infarction.13 Recent studies have, however, suggested 
a poor correlation between survival and LVEF in pa- 
tients with idiopathic or ischemic cardiomyopathy re- 
mote from the acute infarction.14 Similarly a poor cor- 
relation has been reported between maximum oxygen 
consumption during exercise and LVEF in patients 
with CHF.15 However, in a recent study of patients 
with CHF, Baker et all5 found an excellent correlation 
between exercise performance and right ventricular 
(RV) EF as determined by radionuclide ventriculo- 
graphy. Polak et alI4 have emphasized that RVEF is a 
better predictor of survival than LVEF in patients with 
CHF. The reasons for the superiority of RVEF as a 
predictor of exercise performance and survival in pa- 
tients with CHF remain uncertafn. The development 
TABLE II Steps in the Evaluation of a Patient wlth Dilated 
Congestive Cardiomyopathy 
Establish the diagnosis of congestive heart failure and the presence of dilated 
congestive cardiomyopathy 
Evaluate the extent of myocardial dysfunction 
Determine the presence, frequency and complexity of ventricular arrhythmias 
and the propensity for sudden cardiac death 
Rule out myocardial ischemia 
Rule out left ventricular dyskinesis or aneurysm 
Rule out occult myocarditis 
Determine serum electrolytes 
Assess neurohumoral status 
Detect mural thrombus formation 
of RV dysfunction in conjunction with LV dysfunction 
may impair the patient’s ability to increase cardiac 
output during stress, thus compromising exercise per- 
formance and perhaps precipitating sudden cardiac 
death by secondary neurohumoral mechanisms. The 
recent observation that the atria1 natriuretic factor is 
regulated at least in part by the level of right atria1 
pressure, and the finding of elevated levels in CHF 
patients,‘” raise the possibility that this and other neu- 
rohumoral mechanisms are important to our under- 
standing of how right ventricle function affects surviv- 
al in patients with CHF. 
Determining the Presence, Frequency 
and Complexity of Ventricular Arrhythmias 
and the Propensity for Sudden Cardiac Death 
Frequent and complex ventricular arrhythmias in a 
patient with ischemic cardiomyopathy appear to inde- 
pendently increase the risk of sudden cardiac death.17 
The prognostic value of ventricular arrhythmias in a 
patient with idiopathic dilated cardiomyopathy is less 
certain.18 The role of ambulatory Holter electrocardio- 
graphic recordings and electrophysiologic testing in 
patients with CHF has been reviewed by Francis in 
this issue.18 
Ruling Out Myocardial schemia 
The presence of ischemic cardiomyopathy, as well 
as reversible or inducible myocardial ischemia, must 
be established. Exercise, emotional stress or myocardi- 
al ischemia may all trigger ventricular arrhythmias in a 
patient with CHF. However, antiarrhythmic therapy to 
prevent sudden cardiac death will probably not be 
effective in patients with ischemia-induced arrhyth- 
mias, unless appropriate antianginal agents or anti- 
ischemic strategies are applied. 
The differentiation of ischemic from idiopathic di- 
lated cardiomyopathy has proven difficult by noninva- 
sive techniques. The detection of a large LV dyskinetic 
area or aneurysm by chest x-ray, echocardiography or 
radionuclide ventriculography is highly suggestive of 
ischemic cardiomyopathy. Patients with idiopathic di- 
lated cardiomyopathy, especially those with alcoholic 
cardiomyopathy, may have abnormalities of regional 
myocardial wall motion and focal thallium-201 de- 
fects.lg Conversely, patients with ischemic cardiomy- 
‘opathy may have diffuse LV hypokinesis. In an early 
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study using thallium-201 myocardial imaging, we eval- 
uated the possibility of distinguishing patients with 
ischemic cardiomyopathy from those with idiopathic 
dilated cardiomyopathy.19 Patients with ischemic car- 
diomyopathy were found to have relatively large de- 
fects in thallium-201 uptake corresponding to large 
areas of myocardial scarring, while those with idio- 
pathic cardiomyopathy had uniform thallium-201 
uptake or only relatively small defects in uptake. How- 
ever, subsequent studies have had difficulty distin- 
guishing ischemic cardiomyopathy from idiopathic di- 
lated cardiomyopathy using thallium-201.20 Radionu- 
elide ventriculography and echocardiography have 
also been used in differentiating ischemic from idio- 
pathic dilated cardiomyopathy. Shen et al21 recently 
used rest-exercise radionuclide ventriculography to 
compare 24 patients with dilated cardiomyopathy (13 
patients had idiopathic cardiomyopathy, 11 had prior 
myocardial infarction] to 6 age-matched control sub- 
jects. The LVEF during exercise increased significant- 
ly in patients with idiopathic dilated cardiomyopathy 
compared with an insignificant increase in those with 
ischemic cardiomyopathy. On the basis of this study, 
the authors suggest that idiopathic cardiomyopathy 
can be distinguished from ischemic cardiomyopathy. 
It is, however, likely that patients with idiopathic dilat- 
ed cardiomyopathy have variable LVEFs in response 
to exercise; in some patients LVEFs are increased dur- 
ing exercise, while in others they are decreased or 
maintainedez2 
At the moment, coronary angiography may be the 
only reliable means of distin~ishing idiopathic from 
ischemic cardiomyopathy. I do not, however, believe 
that coronary angiography is justified in all patients 
with dilated cardiomyopathy. Although patients with 
ischemic cardiomyopathy appear to have a worse 
prognosis than those with idiopathic cardiomyopathy, 
the critical question for clinical decision-making is not 
whether ischemic cardiomyopathy is present, but 
whether there is evidence of residual reversible myo- 
cardial ischemia. A new defect in thallium-201 uptake 
or the redistribution of thallium-201 after exercise sug- 
gests reversible myocardial ischemia and requires fur- 
ther investigation by coronary angiography, antiische- 
mic therapy or both. Although this approach may yield 
a number of false-positive results, [i.e., a reversible 
defect in thallium-201 uptake may occur in a patient 
with idiopathic dilated cardiomyopathy due to relative 
myocardial wall thinning), it generally avoids the need 
for coronary angiography in most patients with idio- 
pathic dilated cardiomyopathy‘ Thus, the detection of 
reversible myocardial ischemia or a discrete LV aneu- 
rysm is more therapeutically important in preventing 
sudden cardiac death than the anatomic detection of 
diffuse coronary artery disease or myocardial scarring. 
Ruling Out left Ventricular Ryskinesis 
or Aneurysm 
Evaluation for a possible discrete LV aneurysm is 
particularly important in a patient with dilated cardio- 
myopathy and ventricular arrhythmias. A recent study 
by Meizlish et alz3 suggested that a discrete area of LV 
dys~nesis or aneu~sm fo~ation in a post-infarction 
patient may be a more significant predictor of sudden 
cardiac death than the LVEF alone. In a group of 51 
patients who had experienced anterior myocardial in- 
farctions, 18 developed functional LV aneurysms. Al- 
though the LVEF was similar in both groups (27 f 10% 
versus 31 f 1270, respectively], l-year mortality was 
significantly different. Those with an LV aneurysm 
had a 61% mortality rate at 1 year compared with only 
19% in those without an aneurysm (p <O.OOl). Six of 
the 11 deaths (55%) in patients with aneurysm were 
sudden. In fact, an LV aneu~sm in a patient with 
dilated cardiomyopathy and ventricular arrhythmias 
is one of the most significant preventable causes of 
sudden death. Resection of the aneu~sm in conjunc- 
tion with endocardial mapping and ablation of the 
ventricular arrhythmia has been effective in prevent- 
ing sudden death in some patients.z4 
Ruling Out Occult Myoearditis 
A recent prospective study by Vignola et a125 clearly 
pointed out the need to detect occult myocarditis in 
patients with ventricular arrhythmias. No obvious 
cause for arrhythmia was found in 17 of 65 patients 
referred for electrophysiologic evaluation because of 
an episode of sudden cardiac death, ventricular tachy- 
cardia or complex ventricular ectopy. Twelve of these 
17 patients underwent myocardial biopsy. Of these, 6 
(50%) had evidence of lymphocytic myocarditis. There 
were no clinical characteristics that could,have pre- 
dicted the presence of myocarditis in these patients. 
All 6 subsequently received immunosuppressive ther- 
apy. After 6 months, these patients underwent repeat 
electrophysiologic evaluation while not receiving anti- 
arrhythmic agents. No patient had ventricular arrhyth- 
mias, and none could be induced by electrophysiolog- 
ic stimulation. On repeat myocardial biopsy,, lympho- 
cytic infiltration was absent, with varying degrees of 
fibrosis. While the exact incidence of lymphocytic 
myocarditis in patients with ventricular arrhythmias 
and LV dysfunction is uncertain, as is the role of im- 
munosuppressive therapy in these patients, this study 
suggests that myocardial biopsy may be valuable in 
detecting occult myocarditis and in reducing the inci- 
dence of sudden cardiac death in patients without a 
clear cause for their arrhythmias. Myocardial biopsy 
may be especially useful in evaluating patients with 
recent onset cardiomyopathy. Dee et alz6 detected evi- 
dence of myocarditis in 18 of 27 patients with cardio- 
myopathy of less than 6 months duration. In patients 
who had dilated cardiomyopathy for less than 4 weeks, 
they found an 89% incidence of myocarditis. Patients 
with evidence of myocarditis on biopsy tended to show 
improvement in LVEF; however, neither histologic 
nor clinical features could be correlated to increases in 
LVEF, regardless of whether or not immunosuppres- 
sive drugs were used. 
Myocardial biopsy may also detect occult eosino- 
philic myocarditis, While most instances of eosinophil- 
ic myocarditis are associated with peripheral eosino- 
philia, active myocarditis has also been noted in 
patients without peripheral eosinophiIia.27 
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Myocardial biopsy should be considered in all pa- 
tients with recent onset dilated cardiomyopathy in or- 
der to detect occult myocarditis. Myocarditis, howev- 
er, may also be detected noninvasively by gallium-67 
myocardial imaging. 28 In a series of 68 consecutive 
patients with idiopathic dilated cardiomyopathy who 
underwent myocardial biopsy and gallium-67 myocar- 
dial imaging, 6 patients (8%) had biopsy evidence of 
myocarditis.28 Five of these 6 (87%) had positive galli- 
um-67 myocardial images, indicating an inflammatory 
process within the myocardium. The incidence of pos- 
itive gallium-67 myocardial imaging in patients with 
negative biopsies was only 14%. The incidence of 
myocarditis on biopsy in patients with a positive scan 
was 36% compared with only 1.8% in those with a 
negative scan. Gallium-67 myocardial imaging may 
therefore be a useful screening technique for detecting 
occult myocarditis in patients with dilated cardiomy- 
opathy. However, the procedure is technically de- 
manding and a relatively large number of false-nega- 
tive results may occur in institutions that do not have 
considerable expertise with it. Until more experience 
is acquired in more centers, we prefer to rely on myo- 
cardial biopsies to detect occult myocarditis. It should 
be emphasized that biopsy interpretation also requires 
an experienced pathologist. Thus, while occult myo- 
carditis may be an important reversible cause of idio- 
pathic dilated cardiomyopathy and sudden cardiac 
death, its true role cannot be known until considerably 
more data are gathered in a large number of patients 
from several centers. 
Myocardial biopsies in patients with dilated cardio- 
myopathy may, however, gain further acceptance 
pending confirmation of a recent study by Figula et 
al.zg In their study, 4.2 patients with congestive cardio- 
myopathy were followed for a mean of 32 f 20 months 
after myocardial biopsy. On follow-up, 20 patients 
(48%) showed hemodynamic deterioration; 5 died of 
progressive CHF. Twenty-two patients (52%) showed 
hemodynamic improvement or stabilization on fol- 
low-up; only 1 patient died of noncardiac cause. Endo- 
myocardial biopsy with quantification of myofibrillar 
cell volume showed a 96% sensitivity and 94% speci- 
ficity for predicting hemodynamic deterioration or 
death. In view of the potential prognostic and thera- 
peutic information obtained from myocardial biopsy 
in patients with recent onset or unexplained cardio- 
myopathy, further systematic study of this technique is 
clearly indicated. 
Determining Serum Electrolytes 
Hypokalemia is common in patients with CHF 
treated with diuretics, and may predispose patients to 
digitalis-induced arrhythmias. Johannsson30 found a 
20% to 25% incidence of hypokalemia in patients with 
CHF. He also pointed out that oral potassium supple- 
mentation may not be effective in CHF patients due to 
poor intestinal absorption, poor compliance or both. 
Patients with CHF who are on a low salt diet and 
taking diuretics may also develop hypochloremic alka- 
Iosis, which must be corrected with potassium chlo- 
ride.31 In some patients, hypokalemia can only be ame- 
liorated after administration of magnesium. Dyckner 
et a132 used muscle biopsies to evaluate tissue magne- 
sium levels and reported a 65% incidence of hypo- 
magnesemia in patients with CHF treated with diure- 
tics. Potassium-sparing diuretics, such as amelioride, 
triameterene or spironolactone, correct both hypoka- 
lemia and hypomagnesemia. 
Hypokalemia and hypomagnesemia in patients 
with CHF may predispose to ventricular arrhythmias 
and sudden cardiac death, especially in patients re- 
ceiving concurrent digitalis therapy. Recent studies 
have shown a good correlation between serum potassi- 
um levels and the frequency of ventricular arrhyth- 
mias in patients with acute infarction.33 The high lev- 
els of serum catecholamines found in CHF patients 
could further aggravate this situation and drive potas- 
sium into the cells as a result of fi2-adrenergic stimula- 
tion. Burch et a134 called attention to the cardiac causes 
of hypomagnesemia, including CHF. Hypomagnese- 
mia can result in ventricular tachycardia, torsade de 
pointes, digitalis-induced arrhythmias and sudden 
cardiac death. 
Of interest is a recent study by Kay et a1,35 which 
reviewed 32 patients with torsade de pointes. Antiar- 
rhythmic agents such as procainamide, quinidine, dis- 
opyramide, mexiletine and amiodarone in conjunc- 
tion with hypokalemia and hypomagnesemia were 
associated with the development of torsade de pointes. 
Serum drug levels were within the therapeutic range 
in 20 of 26 evaluated patients. Twenty of 32 patients 
had prolonged QT intervals, hypokalemia or hypo- 
magnesemia before the administration of antiarrhyth- 
mics. These arrhythmias were not benign: 5 of 32 pa- 
tients died as a direct result of torsade de pointes.35 
The exact role of hypokalemia and hypomagnesemia 
in the development of sudden cardiac death in pa- 
tients with dilated cardiomyopathy can only be specu- 
lated. In the patient with CHF, a relatively high dose of 
diuretics, the concurrent use of digitalis, inadequate 
absorption of potassium supplements, high baseline 
catecholamine levels and a decreased threshold for 
ventricular fibrillation all predispose to sudden cardi- 
ac death. These factors suggest the need for more fre- 
quent monitoring of serum potassium and magnesium 
levels in CHF patients, and cautious administration of 
antiarrhythmic agents. The use of potassium-sparing 
diuretics should be considered in patients with a histo- 
ry of poor compliance to medication, electrocardio- 
graphic evidence of prolonged QT intervals, hypoka- 
lemia or hypomagnesemia. They are not indicated in 
patients with renal impairment or in combination with 
converting enzyme inhibitors, such as captopril, which 
predispose to hyperkalemia. It should also be empha- 
sized that potassium-sparing diuretics may themselves 
predispose the patient to hyperkalemia and ventricu- 
lar arrhythmias, 
Assessing Neurohumoral Status 
Recent studies have shown that baseline norepi- 
nephrine levels may have prognostic value in a patient 
with CHF.36 Release of norepinephrine from myocar- 
dial stores may predispose the CHF patient to ventric- 
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ular arrhythmias and sudden cardiac death, especially 
in conjunction with ischemia or hypokalemia, or it 
may increase myocardial cytolysis with resultant pro- 
gressive heart failure. Because agents that increase 
serum norepinephrine levels, such as nitroprusside or 
hydralazine, can predispose the patient to ventricular 
arrhythmias, agents, such as captopril, that do not in- 
crease serum norepinephrine levels will undoubtedly 
be used increasingly in the future. 
Other neurohumoral agents, such as renin, vaso- 
pressin and atria1 natriuretic factor, are also elevated 
in patients with CHF. *6,37 These agents in conjunction 
with altered prostaglandin metabolites and elevated 
serum catecholamine levels are probably important in 
the etiology of sudden cardiac death in the patient with 
CHF and ventricular arrhythmias. Interestingly, the 
greatest reduction in sudden cardiac death in patients 
with a history of CHF has been observed after treat- 
ment with fl blockers. Patients with a history of CHF 
before infarction or at the onset of infarction who were 
treated with propranolol had a 47% reduction in sud- 
den cardiac death on follow-up, compared with only a 
12% decrease in sudden cardiac death in those with- 
out a history of CHF. 3* Similarly, still controversial 
data from Sweden suggest that ,8-adrenergic blockade 
can increase exercise capacity and cardiac function in 
patients with dilated cardiomyopathy.3g Therefore, the 
evaluation and manipulation of neurohumoral status 
may help reduce the incidence of sudden cardiac 
death and possibly progressive heart failure as well in 
patients with dilated cardiomyopathy. 
Detecting Mural Thrombus Formation 
Mural thrombus formation is relatively frequent in 
patients with dilated congestive cardiomyopathy, es- 
pecially in those with ischemic cardiomyopathy and 
discrete areas of LV dyskinesis. According to Fuster et 
a140 the incidence of thromboembolic episodes in pa- 
tients with CHF was 18%. A mural thrombus can be 
detected by echocardiography, computed tomographic 
imaging and indium-111 myocardial imaging. Treat- 
ment with long-term anticoagulant therapy reduced 
the incidence of thromboembolic events in patients 
with CHF and should be standard therapy if not con- 
traindicated.4O The role of lytic therapy with intrave- 
nous streptokinase or tissue plasminogen activator 
must still be determined. 
In summary, new diagnostic and therapeutic ap- 
proaches are necessary to reduce the mortality of pa- 
tients with CHF and ventricular arrhythmias. Never- 
theless, our failure to decrease mortality in these 
patients may not entirely lie in the lack of effective 
treatment but rather in our failure to apply properly 
the diagnostic and therapeutic approaches now avail- 
able. Efforts should be increased to detect potentially 
reversible causes of sudden cardiac death and pro- 
gressive heart deterioration. The possibility of revers- 
ible myocardial ischemia, LV aneurysm and occult 
myocarditis must be ruled out. Greater effort is neces- 
sary to detect and correct hypokalemia, hypomagnese- 
mia and neurohumoral abnormalities. Although 
potentially reversible causes of dilated congestive 
cardiomyopathy may be relatively infrequent, a more 
aggressive diagnostic approach is justified in an at- 
tempt to detect and correct those factors that may pre- 
dispose the patient to progressive heart failure and 
sudden cardiac death. 
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